17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia

17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia

Abstract Chronic lymphocytic leukemia (CLL) is the most common type of leukemia and the anti-CD20 monoclonal antibody, rituximab, represents the therapeutic gold standard for more than 2 decades in this pathology, when used in combination with chemotherapy. However, some patients experience treatmen...

Full description

Bibliographic Details
Main Authors: Cristina Bagacean, Adrian Tempescul, David Ternant, Anne Banet, Nathalie Douet-Guilbert, Anne Bordron, Boutahar Bendaoud, Hussam Saad, Mihnea Zdrenghea, Christian Berthou, Gilles Paintaud, Yves Renaudineau
Format: Article
Language:English
Published: BMJ Publishing Group 2019-01-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Chronic lymphocytic leukemia
Anti-CD20 monoclonal antibody
Rituximab
Pharmacokinetics
Clearance
17p deletion
Online Access:http://link.springer.com/article/10.1186/s40425-019-0509-0

Internet

http://link.springer.com/article/10.1186/s40425-019-0509-0

Similar Items